JP2008528624A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008528624A5 JP2008528624A5 JP2007553324A JP2007553324A JP2008528624A5 JP 2008528624 A5 JP2008528624 A5 JP 2008528624A5 JP 2007553324 A JP2007553324 A JP 2007553324A JP 2007553324 A JP2007553324 A JP 2007553324A JP 2008528624 A5 JP2008528624 A5 JP 2008528624A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- substituted
- unsubstituted
- alkyl
- member selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 6
- 208000031886 HIV Infections Diseases 0.000 claims description 4
- 208000037357 HIV infectious disease Diseases 0.000 claims description 4
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 4
- -1 methoxy, vinyl Chemical group 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 102100034343 Integrase Human genes 0.000 claims 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 2
- 101100240519 Caenorhabditis elegans nhr-13 gene Proteins 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 1
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- 229960002555 zidovudine Drugs 0.000 description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960001997 adefovir Drugs 0.000 description 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine mesylate Natural products CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 229960001203 stavudine Drugs 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64802705P | 2005-01-28 | 2005-01-28 | |
| PCT/US2006/003217 WO2006081554A2 (en) | 2005-01-28 | 2006-01-30 | Phenyl-substituted pyrrolidones |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008528624A JP2008528624A (ja) | 2008-07-31 |
| JP2008528624A5 true JP2008528624A5 (enExample) | 2009-03-26 |
Family
ID=36741146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007553324A Pending JP2008528624A (ja) | 2005-01-28 | 2006-01-30 | フェニル置換ピロリドン |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20080287516A1 (enExample) |
| EP (1) | EP1841425A4 (enExample) |
| JP (1) | JP2008528624A (enExample) |
| KR (2) | KR100896889B1 (enExample) |
| CN (1) | CN101115481A (enExample) |
| AU (1) | AU2006209245A1 (enExample) |
| BR (1) | BRPI0606123A2 (enExample) |
| CA (1) | CA2594915A1 (enExample) |
| MX (1) | MX2007009137A (enExample) |
| RU (1) | RU2371433C2 (enExample) |
| WO (1) | WO2006081554A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1483283A4 (en) | 2002-03-13 | 2007-04-11 | Signum Biosciences Inc | MODULATION OF PROTEIN METHYLATION AND PHOSPHOPROTEIN PHOSPHATE |
| EP1841424A4 (en) * | 2005-01-28 | 2010-01-27 | Irm Llc | SYNTHESIS OF ARYL PYRROLIDONES |
| US7923041B2 (en) | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| WO2006084033A1 (en) | 2005-02-03 | 2006-08-10 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| JP5164510B2 (ja) * | 2006-10-06 | 2013-03-21 | 日本曹達株式会社 | 含窒素複素環化合物および有害生物防除剤 |
| US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
| AU2009239430B2 (en) | 2008-04-21 | 2015-01-22 | Signum Biosciences, Inc. | Compounds, compositions and methods for making the same |
| US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
| CN101747253B (zh) * | 2008-12-02 | 2013-01-16 | 中国人民解放军军事医学科学院毒物药物研究所 | 三取代的手性内酰胺类衍生物及其制备方法和用途 |
| ES2834451T3 (es) | 2009-05-01 | 2021-06-17 | Aerie Pharmaceuticals Inc | Inhibidores de mecanismo doble para el tratamiento de enfermedades |
| US9238643B2 (en) | 2010-09-06 | 2016-01-19 | Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences | Amide compounds |
| CN101979378B (zh) * | 2010-10-13 | 2012-06-27 | 中国科学院上海有机化学研究所 | 一种手性γ-内酰胺化合物的合成方法 |
| EP2976080B1 (en) | 2013-03-15 | 2019-12-25 | Aerie Pharmaceuticals, Inc. | Conjugates of isoquinoline compounds and prostaglandins |
| MX2019002396A (es) | 2016-08-31 | 2019-07-08 | Aerie Pharmaceuticals Inc | Composiciones oftalmicas. |
| JP2020515583A (ja) | 2017-03-31 | 2020-05-28 | アエリエ ファーマシューティカルズ インコーポレイテッド | アリールシクロプロピル−アミノ−イソキノリニルアミド化合物 |
| CN111479805B (zh) * | 2017-08-29 | 2024-08-13 | 罗格斯新泽西州立大学 | 治疗性吲唑 |
| AU2019337703B2 (en) | 2018-09-14 | 2023-02-02 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
| EP3886854A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU797219A1 (ru) * | 1979-05-08 | 1995-07-25 | Ленинградский государственный педагогический институт им.А.И.Герцена | N-карбамоилметил-4-фенил-2-пирролидон, обладающий гипотензивной активностью |
| TW448172B (en) * | 1996-03-08 | 2001-08-01 | Pharmacia & Upjohn Co Llc | Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation |
| WO2004037784A2 (en) * | 2002-10-21 | 2004-05-06 | Irm Llc | Pyrrolidones with anti-hiv activity |
-
2006
- 2006-01-30 US US11/814,480 patent/US20080287516A1/en not_active Abandoned
- 2006-01-30 AU AU2006209245A patent/AU2006209245A1/en not_active Abandoned
- 2006-01-30 RU RU2007132259/04A patent/RU2371433C2/ru not_active IP Right Cessation
- 2006-01-30 CN CNA2006800033348A patent/CN101115481A/zh active Pending
- 2006-01-30 KR KR1020077017487A patent/KR100896889B1/ko not_active Expired - Fee Related
- 2006-01-30 BR BRPI0606123-0A patent/BRPI0606123A2/pt not_active IP Right Cessation
- 2006-01-30 CA CA002594915A patent/CA2594915A1/en not_active Abandoned
- 2006-01-30 JP JP2007553324A patent/JP2008528624A/ja active Pending
- 2006-01-30 WO PCT/US2006/003217 patent/WO2006081554A2/en not_active Ceased
- 2006-01-30 KR KR1020097004694A patent/KR20090028846A/ko not_active Ceased
- 2006-01-30 MX MX2007009137A patent/MX2007009137A/es not_active Application Discontinuation
- 2006-01-30 EP EP06734052A patent/EP1841425A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008528624A5 (enExample) | ||
| CA3089590C (en) | Pyridine derivatives and their use for treating hiv infection | |
| TWI740910B (zh) | 非環抗病毒劑 | |
| JP2011529918A5 (enExample) | ||
| US20190022116A1 (en) | N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto | |
| WO2008100447A3 (en) | Nucleoside analogs for antiviral treatment | |
| TW201418274A (zh) | ２’－甲基經取代之核苷衍生物及其用於治療病毒疾病之使用方法 | |
| TW201217392A (en) | Substituted nucleotide analogs | |
| KR20170081228A (ko) | 티족사나이드, 그의 유사체 또는 염의 전구 약물을 이용한 치료 조성물 및 방법 | |
| JP2010510301A (ja) | 化合物 | |
| ZA200502384B (en) | Non-nucleoside reverse transcriptase inhibitors | |
| JP2006505543A5 (enExample) | ||
| JP2024038012A (ja) | アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用 | |
| WO2017106710A1 (en) | Nucleotide and nucleoside therapeutic compositions and uses related thereto | |
| JP2005526024A5 (enExample) | ||
| US20190085013A1 (en) | Nucleotide and nucleoside therapeutic compositions and uses related thereto | |
| CN114867351A (zh) | 含4′-卤素的核苷酸和核苷治疗组合物以及其相关用途 | |
| AU2010229975B2 (en) | Process for preparing antiviral compound | |
| KR0130977B1 (ko) | 항종양제로서 폴리아민 유도체 | |
| JP2005519983A (ja) | ヌクレオシド、その調製、及び、ｒｎａウイルスポリメラーゼの阻害剤としてのその使用 | |
| WO2004029064A8 (en) | (+)-trans-isomers of (1-phosphonomethoxy-2-alkylcyclopropyl) methyl nucleoside derivatives, process for the preparation of stereoisomers thereof, and use of antiviral agents thereof | |
| CA2441309A1 (en) | Biguanide derivatives | |
| CN101511185A (zh) | 唑类核苷和作为rna和dna病毒聚合酶抑制剂的用途 | |
| CN107820499B (zh) | 抗病毒化合物、其制备工艺、以及其用于治疗病毒感染的用途 | |
| US20160060228A1 (en) | Process for preparing antiviral compound |